title: Effects of anticancer agents on cell viability, proliferative activity and cytokine production of peripheral blood mononuclear cells.
abstract: We investigated the effects of anticancer agents on peripheral blood mononuclear cells for the purpose of providing data to support new translational chemoimmunotherapy regimens. Peripheral-blood mononuclear cells were treated with one of four anticancer agents (5-fluorouracil, irinotecan, cisplatin, and gemcitabine) for 2 h, after which cell viability was determined. For assessment of effects of each drug on proliferation and cytokine production, cells were stimulated with phytohemagglutinin for 48 h. As a result, the anticancer agents did not affect cell viability. Cell proliferation was unaffected by 5-fluorouracil and irinotecan but inhibited by cisplatin and gemcitabine. Treatment with gemcitabine enhanced the production of IFN-γ and decreased the number of regulatory T cells. gemcitabine treatment increased IFN-γ production among CD4 T cells but not among CD8 T cells. The results indicated that GEM had immunoregulatory properties that might support immune response against cancer. This finding has implications for designing chemoimmunotherapy strategies.
authors: Department of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kamigyo-ku, Kyoto 602-8566, Japan.
authors: Hiromi
authors: H
authors: Sakai
authors: Satoshi
authors: S
authors: Kokura
authors: Takeshi
authors: T
authors: Ishikawa
authors: Reiko
authors: R
authors: Tsuchiya
authors: Manabu
authors: M
authors: Okajima
authors: Tatsuzou
authors: T
authors: Matsuyama
authors: Satoko
authors: S
authors: Adachi
authors: Kazuhiro
authors: K
authors: Katada
authors: Kazuhiro
authors: K
authors: Kamada
authors: Kazuhiko
authors: K
authors: Uchiyama
authors: Osamu
authors: O
authors: Handa
authors: Tomohisa
authors: T
authors: Takagi
authors: Nobuaki
authors: N
authors: Yagi
authors: Yuji
authors: Y
authors: Naito
authors: Toshikazu
authors: T
authors: Yoshikawa
keywords: 5-fluorouracil (5-FU); chemoimmunotherapy; cisplatin (CDDP); gemcitabine (GEM); irinotecan (CPT-11)